You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company plans to increase the capacity of its CLIA-certified laboratory to about 100,000 SARS-CoV-2 tests per day by the end of 2020.
The company also announced John Leite, the former leader of clinical business development activities at Illumina, had joined the firm as chief business officer.
The company plans to use the funding to expand operations in Florida and California and continue commercial growth of its FebriDx test.
The firm will use the funding from Keystone Capital Partners to advance its Cancer Differentiation Analysis technology to offer early detection screening and testing of 26 cancers.
The new company will use Seer's Proteograph proteomic platform along with other omics data to develop and commercialize tests for cancer and other diseases.
The firm said the financing enables it to progress with the development of an algorithm that would help detect the most common cancers.
The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.
Tangen will use the proceeds to scale up manufacturing for its SARS-CoV-2 point-of-care test and accelerate development of a panel test including SARS-CoV-2 targets.
Enzyre is developing a near-patient platform called Enzypad to measure biomarkers in body fluids. The first application will be the monitoring of hemophilia.
The proceeds from the round will allow the firm to begin selling its in vitro diagnostic blood test for patients with chronic kidney disease.